AAPL351.98-4.30 (-1.21%) ▼|ABBV294.62-0.41 (-0.14%) ▼|ABT108.39-0.13 (-0.12%) ▼|ACN251.40+0.91 (+0.36%) ▲|ADBE249.07+5.99 (+2.46%) ▲|AMAT352.20-18.30 (-4.94%) ▼|AMD505.08-28.98 (-5.43%) ▼|AMGN466.92+1.25 (+0.27%) ▲|AMT191.03-0.62 (-0.32%) ▼|AMZN258.50-8.16 (-3.06%) ▼|AVGO331.81-15.20 (-4.38%) ▼|AXP318.55-2.05 (-0.64%) ▼|BA166.14-5.36 (-3.13%) ▼|BAC50.06-0.96 (-1.88%) ▼|BKNG156.95-2.63 (-1.65%) ▼|BLK1,199.56-23.36 (-1.91%) ▼|BMY63.33-0.10 (-0.16%) ▼|BNY151.93-1.48 (-0.96%) ▼|BRK-B593.13+0.19 (+0.03%) ▲|C121.28-2.73 (-2.20%) ▼|CAT574.35-25.85 (-4.31%) ▼|CL101.64+1.97 (+1.98%) ▲|CMCSA25.62+0.46 (+1.83%) ▲|COF192.77-1.51 (-0.78%) ▼|COP140.18-1.17 (-0.83%) ▼|COST1,111.47+5.26 (+0.48%) ▲|CRM216.73-1.11 (-0.51%) ▼|CSCO94.69-0.95 (-0.99%) ▼|CVS88.27-1.08 (-1.21%) ▼|CVX217.25-2.64 (-1.20%) ▼|DE660.11-13.43 (-1.99%) ▼|DHR231.93-1.10 (-0.47%) ▼|DIS118.29-0.68 (-0.57%) ▼|DUK130.38+1.22 (+0.94%) ▲|EMR161.01-5.37 (-3.23%) ▼|FDX326.67+2.53 (+0.78%) ▲|GD359.62-3.84 (-1.06%) ▼|GE326.86-4.95 (-1.49%) ▼|GEV762.96-40.17 (-5.00%) ▼|GILD169.22+1.14 (+0.68%) ▲|GM83.82-2.18 (-2.53%) ▼|GOOG283.67-8.85 (-3.03%) ▼|GOOGL286.53-9.24 (-3.12%) ▼|GS889.70-26.86 (-2.93%) ▼|HD348.19-0.50 (-0.14%) ▼|HON220.06-2.41 (-1.08%) ▼|IBM244.32-2.81 (-1.14%) ▼|INTC55.26-4.41 (-7.38%) ▼|INTU348.99+7.29 (+2.13%) ▲|ISRG441.79-1.80 (-0.41%) ▼|JNJ284.93-0.82 (-0.29%) ▼|JPM338.92-7.27 (-2.10%) ▼|KO99.46+0.21 (+0.21%) ▲|LIN526.32+0.26 (+0.05%) ▲|LLY1,443.31-0.19 (-0.01%) ▼|LMT582.92-13.12 (-2.20%) ▼|LOW226.69-1.05 (-0.46%) ▼|LRCX210.88-15.04 (-6.66%) ▼|MA664.41+3.22 (+0.49%) ▲|MCD276.35+4.38 (+1.61%) ▲|MDLZ68.06+0.52 (+0.76%) ▲|MDT103.30+0.44 (+0.42%) ▲|META624.89-16.80 (-2.62%) ▼|MMM183.26-0.40 (-0.22%) ▼|MO78.81+0.17 (+0.22%) ▲|MRK146.37-1.39 (-0.94%) ▼|MS184.21-6.44 (-3.38%) ▼|MSFT521.11-2.77 (-0.53%) ▼|MU722.39-55.92 (-7.19%) ▼|NEE85.54+0.42 (+0.49%) ▲|NFLX60.87-1.28 (-2.06%) ▼|NKE37.82-0.17 (-0.45%) ▼|NOW100.53-1.72 (-1.69%) ▼|NVDA155.25-7.60 (-4.67%) ▼|ORCL118.96-6.39 (-5.10%) ▼|PEP147.69+2.25 (+1.55%) ▲|PFE28.95+0.06 (+0.19%) ▲|PG173.13+3.33 (+1.96%) ▲|PLTR161.10-6.89 (-4.10%) ▼|PM196.43-2.53 (-1.27%) ▼|QCOM170.86-1.61 (-0.93%) ▼|RTX195.70-2.88 (-1.45%) ▼|SBUX108.04+1.60 (+1.50%) ▲|SCHW93.34+0.36 (+0.38%) ▲|SO94.08+1.25 (+1.35%) ▲|SPG231.12-1.85 (-0.79%) ▼|T22.31+0.13 (+0.56%) ▲|TMO695.19-5.03 (-0.72%) ▼|TMUS171.88+1.93 (+1.14%) ▲|TSLA378.61-11.62 (-2.98%) ▼|TXN295.91-7.70 (-2.53%) ▼|UBER69.67-0.02 (-0.03%) ▼|UNH410.10+2.64 (+0.65%) ▲|UNP304.43+1.99 (+0.66%) ▲|UPS111.29+0.53 (+0.48%) ▲|USB60.44-0.55 (-0.90%) ▼|V427.39+1.63 (+0.38%) ▲|VZ46.43+0.07 (+0.15%) ▲|WFC84.38-1.68 (-1.95%) ▼|WMT128.25+0.16 (+0.12%) ▲|XOM167.38-2.14 (-1.26%) ▼|AAPL351.98-4.30 (-1.21%) ▼|ABBV294.62-0.41 (-0.14%) ▼|ABT108.39-0.13 (-0.12%) ▼|ACN251.40+0.91 (+0.36%) ▲|ADBE249.07+5.99 (+2.46%) ▲|AMAT352.20-18.30 (-4.94%) ▼|AMD505.08-28.98 (-5.43%) ▼|AMGN466.92+1.25 (+0.27%) ▲|AMT191.03-0.62 (-0.32%) ▼|AMZN258.50-8.16 (-3.06%) ▼|AVGO331.81-15.20 (-4.38%) ▼|AXP318.55-2.05 (-0.64%) ▼|BA166.14-5.36 (-3.13%) ▼|BAC50.06-0.96 (-1.88%) ▼|BKNG156.95-2.63 (-1.65%) ▼|BLK1,199.56-23.36 (-1.91%) ▼|BMY63.33-0.10 (-0.16%) ▼|BNY151.93-1.48 (-0.96%) ▼|BRK-B593.13+0.19 (+0.03%) ▲|C121.28-2.73 (-2.20%) ▼|CAT574.35-25.85 (-4.31%) ▼|CL101.64+1.97 (+1.98%) ▲|CMCSA25.62+0.46 (+1.83%) ▲|COF192.77-1.51 (-0.78%) ▼|COP140.18-1.17 (-0.83%) ▼|COST1,111.47+5.26 (+0.48%) ▲|CRM216.73-1.11 (-0.51%) ▼|CSCO94.69-0.95 (-0.99%) ▼|CVS88.27-1.08 (-1.21%) ▼|CVX217.25-2.64 (-1.20%) ▼|DE660.11-13.43 (-1.99%) ▼|DHR231.93-1.10 (-0.47%) ▼|DIS118.29-0.68 (-0.57%) ▼|DUK130.38+1.22 (+0.94%) ▲|EMR161.01-5.37 (-3.23%) ▼|FDX326.67+2.53 (+0.78%) ▲|GD359.62-3.84 (-1.06%) ▼|GE326.86-4.95 (-1.49%) ▼|GEV762.96-40.17 (-5.00%) ▼|GILD169.22+1.14 (+0.68%) ▲|GM83.82-2.18 (-2.53%) ▼|GOOG283.67-8.85 (-3.03%) ▼|GOOGL286.53-9.24 (-3.12%) ▼|GS889.70-26.86 (-2.93%) ▼|HD348.19-0.50 (-0.14%) ▼|HON220.06-2.41 (-1.08%) ▼|IBM244.32-2.81 (-1.14%) ▼|INTC55.26-4.41 (-7.38%) ▼|INTU348.99+7.29 (+2.13%) ▲|ISRG441.79-1.80 (-0.41%) ▼|JNJ284.93-0.82 (-0.29%) ▼|JPM338.92-7.27 (-2.10%) ▼|KO99.46+0.21 (+0.21%) ▲|LIN526.32+0.26 (+0.05%) ▲|LLY1,443.31-0.19 (-0.01%) ▼|LMT582.92-13.12 (-2.20%) ▼|LOW226.69-1.05 (-0.46%) ▼|LRCX210.88-15.04 (-6.66%) ▼|MA664.41+3.22 (+0.49%) ▲|MCD276.35+4.38 (+1.61%) ▲|MDLZ68.06+0.52 (+0.76%) ▲|MDT103.30+0.44 (+0.42%) ▲|META624.89-16.80 (-2.62%) ▼|MMM183.26-0.40 (-0.22%) ▼|MO78.81+0.17 (+0.22%) ▲|MRK146.37-1.39 (-0.94%) ▼|MS184.21-6.44 (-3.38%) ▼|MSFT521.11-2.77 (-0.53%) ▼|MU722.39-55.92 (-7.19%) ▼|NEE85.54+0.42 (+0.49%) ▲|NFLX60.87-1.28 (-2.06%) ▼|NKE37.82-0.17 (-0.45%) ▼|NOW100.53-1.72 (-1.69%) ▼|NVDA155.25-7.60 (-4.67%) ▼|ORCL118.96-6.39 (-5.10%) ▼|PEP147.69+2.25 (+1.55%) ▲|PFE28.95+0.06 (+0.19%) ▲|PG173.13+3.33 (+1.96%) ▲|PLTR161.10-6.89 (-4.10%) ▼|PM196.43-2.53 (-1.27%) ▼|QCOM170.86-1.61 (-0.93%) ▼|RTX195.70-2.88 (-1.45%) ▼|SBUX108.04+1.60 (+1.50%) ▲|SCHW93.34+0.36 (+0.38%) ▲|SO94.08+1.25 (+1.35%) ▲|SPG231.12-1.85 (-0.79%) ▼|T22.31+0.13 (+0.56%) ▲|TMO695.19-5.03 (-0.72%) ▼|TMUS171.88+1.93 (+1.14%) ▲|TSLA378.61-11.62 (-2.98%) ▼|TXN295.91-7.70 (-2.53%) ▼|UBER69.67-0.02 (-0.03%) ▼|UNH410.10+2.64 (+0.65%) ▲|UNP304.43+1.99 (+0.66%) ▲|UPS111.29+0.53 (+0.48%) ▲|USB60.44-0.55 (-0.90%) ▼|V427.39+1.63 (+0.38%) ▲|VZ46.43+0.07 (+0.15%) ▲|WFC84.38-1.68 (-1.95%) ▼|WMT128.25+0.16 (+0.12%) ▲|XOM167.38-2.14 (-1.26%) ▼|
13 C
New York
Monday, November 16, 2026

Tag: development

How to participate in Quid Miner cloud mining and earn passive income every day using XRP or DOGE

Boston, Massachusetts, June 21, 2025 (GLOBE NEWSWIRE) -- In the dynamic cryptocurrency market, XRP and DOGE have always attracted much attention. XRP, with its advantages in the field of cross-border payments, is seen as a bridge connecting traditional finance and blockchain; and DOGE has quickly become popular and a market hotspot relying on its strong community support and star effect. As the market gradually becomes standardized and supervision is strengthened, the development directions of the two cryptocurrencies have begun to diverge significantly.



The latest data shows that after a round of strong growth, XRP's price is currently trading sideways in a key range, and market momentum has slowed down. At the same time, DOGE's technical side is weak and faces pullback pressure in the short term. Despite this, some large investors continue to increase their positions in DOGE, indicating that its long-term prospects are still optimistic. In the current market environment, more and more investors are beginning to seek more stable and sustainable ways to return. At this time, the launch of QuidMiner provides them with a new option.

Providing potential cryptocurrency mining solutions to investors

Quid Miner was founded in 2010 and is headquartered in the UK. It is a regulated cloud mining platform that serves more than 8 million users in more than 180 countries around the world. Quid Miner deeply integrates artificial intelligence and green renewable energy and applies them to the cloud mining field. Quid Miner is committed to making cloud mining simple, efficient and safe. Relying on advanced technology and a global network of data centers,Quid Miner allows users to easily participate in the blockchain ecosystem and earn potential passive income without having to purchase hardware or maintain equipment.

QuidMiner platform core advantages:

⦁ Register and log in to get a $15 reward (a daily $0.60 sign-in bonus)

⦁ Simple interface and convenient operation: all fee structures are fully open and transparent, without any hidden fees. Provide a variety of flexible contract options

⦁ The platform supports more than 10 cryptocurrencies for settlement (recharge and withdrawal): including DOGE, BTC, ETH, SOL, BCH, XRP, USDC, LTC, USDT-TRC20 and USDT-ERC20, etc.

⦁ Referral Affiliate Program: Recommend your friends to register and you will receive referral bonus permanently.

⦁ Relying on the dual protection of McAfee® and Cloudflare®, it provides stable operation support and 7x24 hours of real-time technical customer service to ensure user safety.

Start your mining journey in 3 simple steps

⦁Visit the official website of quidminer and register as a member immediately via email.

⦁Choose a mining contract that suits your budget and start your mining plan easily.

⦁Referral Affiliate Program: Refer friends to register and get potential referral rewards

Learn about QuidMiner mining contracts and explore new ways to manage digital assets

(Note:Please configure flexibly and reasonably according to your own budget and choose a variety of contracts that suit you. You will have the opportunity to obtain potential profits. Your potential profits will be automatically calculated and settled in your account.)

In summary

As the uncertainty in the cryptocurrency market intensifies, QuidMiner has attracted more and more users' attention with its advanced security technology architecture features, compliant and transparent operating system, and simple and intuitive user experience. Whether you are a beginner or a seasoned veteran investor,QuidMiner provides you with a potential passive income solution.

For more information, please visit the official website of the platform: https://quidminer.com/

APP application download

Official platform email: info@quidminer.org

Disclaimer: The information provided in this press release is not a solicitation to invest and is not intended as investment advice, financial advice, or trading advice. Cryptocurrency mining and staking involve risks. There is a possibility of loss of funds. You are strongly advised to perform due diligence before investing or trading in cryptocurrencies and securities, including consulting a professional financial advisor.

Lilly’s oral GLP-1, orforglipron, showed compelling efficacy and a safety profile consistent with injectable GLP-1 medicines, in complete Phase 3 results published in The...

The investigational once-daily pill lowered A1C by an average of 1.3% to 1.6% across doses, with improvements seen as early as four weeks, in adults...

MetaVia Presents Pre-Clinical Data on DA-1241 Demonstrating Additive Hepatoprotective Effects in Combination With Efruxifermin at the ADA’s 85th Scientific Session

CAMBRIDGE, Mass., June 21, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the presentation of...

New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine

The full results of the phase IV RESOLUTION trial were presented at the European Academy of Neurology 2025 Annual Congress, where Vyepti® (eptinezumab) demonstrated...

New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine

The full results of the phase IV RESOLUTION trial were presented at the European Academy of Neurology 2025 Annual Congress, where Vyepti® (eptinezumab) demonstrated...

New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine

The full results of the phase III registrational SUNRISE trial were presented at the European Academy of Neurology 2025 Annual Congress, where eptinezumab demonstrated statistically...

New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine

The full results of the phase III registrational SUNRISE trial were presented at the European Academy of Neurology 2025 Annual Congress, where eptinezumab demonstrated statistically...

IIM Udaipur Concludes Executive Education Training Program for PM SHRI School Principals in Collaboration with RSSP Jaipur

UDAIPUR, India, June 21, 2025 /PRNewswire/ -- Indian Institute of Management Udaipur (IIM Udaipur), in collaboration with the Rajasthan School Shiksha Parishad (RSSP), Jaipur,...

Dialogue on China-ASEAN Cultural Heritage Successfully Concludes in Tianshui

TIANSHUI, China, June 21, 2025 /PRNewswire/ -- To encourage exchange and cooperation in cultural heritage preservation, promote mutual learning among civilizations, and advance the...

Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association’s 85th Scientific Sessions

In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly...

Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association’s 85th Scientific Sessions

In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly...

Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association’s 85th Scientific Sessions

In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly...

SIFF 2025: The Premier Launchpad for Chinese Movies and Their Global Promotion

SHANGHAI, June 21, 2025 /PRNewswire/ -- The 27th Shanghai International Film Festival (SIFF) is currently in full swing, vividly demonstrating the booming momentum of...

Potential Tax Changes Under Trump—Evaluate the Impact on Holiday Financial Planning

In 2012, I encountered Dane Chapin, a seasoned entrepreneur from San Diego, who challenged my views on climate change during a conversation in his...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsDevelopment